248 related articles for article (PubMed ID: 31693900)
1. Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.
Ilca FT; Drexhage LZ; Brewin G; Peacock S; Boyle LH
Cell Rep; 2019 Nov; 29(6):1621-1632.e3. PubMed ID: 31693900
[TBL] [Abstract][Full Text] [Related]
2. TAPBPR mediates peptide dissociation from MHC class I using a leucine lever.
Ilca FT; Neerincx A; Hermann C; Marcu A; Stevanović S; Deane JE; Boyle LH
Elife; 2018 Nov; 7():. PubMed ID: 30484775
[TBL] [Abstract][Full Text] [Related]
3. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap.
McShan AC; Devlin CA; Morozov GI; Overall SA; Moschidi D; Akella N; Procko E; Sgourakis NG
Nat Commun; 2021 May; 12(1):3174. PubMed ID: 34039964
[TBL] [Abstract][Full Text] [Related]
4. The binding of TAPBPR and Tapasin to MHC class I is mutually exclusive.
Hermann C; Strittmatter LM; Deane JE; Boyle LH
J Immunol; 2013 Dec; 191(11):5743-50. PubMed ID: 24163410
[TBL] [Abstract][Full Text] [Related]
5. A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor.
Sagert L; Hennig F; Thomas C; Tampé R
Elife; 2020 Mar; 9():. PubMed ID: 32167472
[TBL] [Abstract][Full Text] [Related]
6. The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.
Ilca FT; Boyle LH
Mol Immunol; 2021 Nov; 139():168-176. PubMed ID: 34543843
[TBL] [Abstract][Full Text] [Related]
7. Reanalysis of Immunopeptidomics Datasets Provides Mechanistic Insight into TAPBPR-Mediated Peptide Editing on HLA-A, -B and -C Molecules.
Altenburg AF; Morley JL; Bauer J; Walz JS; Boyle LH
Wellcome Open Res; 2024; 9():113. PubMed ID: 38800518
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of chaperone interactions on MHC-I for folding and antigen repertoire selection.
McShan AC; Devlin CA; Overall SA; Park J; Toor JS; Moschidi D; Flores-Solis D; Choi H; Tripathi S; Procko E; Sgourakis NG
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25602-25613. PubMed ID: 31796585
[TBL] [Abstract][Full Text] [Related]
9. Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation.
Neerincx A; Boyle LH
Mol Immunol; 2019 Sep; 113():58-66. PubMed ID: 30077416
[TBL] [Abstract][Full Text] [Related]
10. TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.
Hermann C; van Hateren A; Trautwein N; Neerincx A; Duriez PJ; Stevanović S; Trowsdale J; Deane JE; Elliott T; Boyle LH
Elife; 2015 Oct; 4():. PubMed ID: 26439010
[TBL] [Abstract][Full Text] [Related]
11. Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway.
Boyle LH; Hermann C; Boname JM; Porter KM; Patel PA; Burr ML; Duncan LM; Harbour ME; Rhodes DA; Skjødt K; Lehner PJ; Trowsdale J
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3465-70. PubMed ID: 23401559
[TBL] [Abstract][Full Text] [Related]
12. Properties of the tapasin homologue TAPBPR.
Neerincx A; Boyle LH
Curr Opin Immunol; 2017 Jun; 46():97-102. PubMed ID: 28528220
[TBL] [Abstract][Full Text] [Related]
13. Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules.
Ilca FT; Neerincx A; Wills MR; de la Roche M; Boyle LH
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9353-E9361. PubMed ID: 30213851
[TBL] [Abstract][Full Text] [Related]
14. Xeno interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes.
Sun Y; Papadaki GF; Devlin CA; Danon JN; Young MC; Winters TJ; Burslem GM; Procko E; Sgourakis NG
Sci Adv; 2023 Feb; 9(8):eade7151. PubMed ID: 36827371
[TBL] [Abstract][Full Text] [Related]
15. Molecular architecture of the MHC I peptide-loading complex: one tapasin molecule is essential and sufficient for antigen processing.
Hulpke S; Baldauf C; Tampé R
FASEB J; 2012 Dec; 26(12):5071-80. PubMed ID: 22923333
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR.
Xu H; Song K; Da LT
Phys Chem Chem Phys; 2022 May; 24(20):12397-12409. PubMed ID: 35575131
[TBL] [Abstract][Full Text] [Related]
17. TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway.
Neerincx A; Hermann C; Antrobus R; van Hateren A; Cao H; Trautwein N; Stevanović S; Elliott T; Deane JE; Boyle LH
Elife; 2017 Apr; 6():. PubMed ID: 28425917
[TBL] [Abstract][Full Text] [Related]
18. Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing.
Morozov GI; Zhao H; Mage MG; Boyd LF; Jiang J; Dolan MA; Venna R; Norcross MA; McMurtrey CP; Hildebrand W; Schuck P; Natarajan K; Margulies DH
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):E1006-15. PubMed ID: 26869717
[TBL] [Abstract][Full Text] [Related]
19. Peptide exchange on MHC-I by TAPBPR is driven by a negative allostery release cycle.
McShan AC; Natarajan K; Kumirov VK; Flores-Solis D; Jiang J; Badstübner M; Toor JS; Bagshaw CR; Kovrigin EL; Margulies DH; Sgourakis NG
Nat Chem Biol; 2018 Aug; 14(8):811-820. PubMed ID: 29988068
[TBL] [Abstract][Full Text] [Related]
20. TAPBPR: a new player in the MHC class I presentation pathway.
Hermann C; Trowsdale J; Boyle LH
Tissue Antigens; 2015 Mar; 85(3):155-66. PubMed ID: 25720504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
